The latest version of the National Comprehensive Cancer Network (NCCN) guidelines recommends BRAF inhibitors in combination with MEK inhibitors as one of the first-line treatments for unresectable melanoma with BRAF mutations [9]. Here, BRAF is linked to melanoma.